Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketorolac is a potent, short-term nonsteroidal anti-inflammatory drug (NSAID) used primarily for the management of moderate to severe acute pain, often as an alternative or adjunct to opioid analgesics. It is a non-selective cyclooxygenase (COX) inhibitor that reduces prostaglandin synthesis, resulting in analgesic, anti-inflammatory, and antipyretic effects. Ketorolac is available in several formulations including oral tablets, intramuscular and intravenous injections, nasal spray, and ophthalmic solutions. Its onset of action is rapid (within 30–60 minutes), with peak effect at 1–2 hours and duration up to 6–8 hours. The recommended treatment duration does not exceed five days due to risk of serious adverse effects such as gastrointestinal bleeding and renal impairment[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorolac.